Journal of the Japan Diabetes Society
Online ISSN : 1881-588X
Print ISSN : 0021-437X
ISSN-L : 0021-437X
Search
Advanced search
OR
Browse
Search
Volume 51, Issue 3
Displaying 1-16 of 16 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
The Diagnosis and Treatment of Diabetes with Particular Pathogenesis
Original Article
  • The Effect of Diastolic Dysfunction and Hypertension in Diabetes Mellitus
    —Examination of Left Ventricular Diastolic Dysfunction using the Valsalva Maneuver—
    Shu Abe, Shigeru Ohta, Kenzo Uchida
    2008 Volume 51 Issue 3 Pages 213-218
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.213
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We determined the effects of diabetes mellitus on left ventricular (LV) diastolic function in normotensive and hypertensive subjects. The ratio of early to late peak flow velocity (E/A ratio) and deceleration time were obtained from Doppler recordings in the apical 4-chamber view with the sample volume placed at the tip of the mitral valve. The same measurements were then repeated during the Valsalva maneuver to unmask LV diastolic function abnormalities (pseudonormalization) for measuring%E/A ratio. The Valsalva maneuver helped differentiate between patients with and without pseudonormal diastolic dysfunction. The prevalence of diastolic dysfunction was lowest in patients with hypertension, intermediate in patients with diabetes mellitus, and highest in patients with both diabetes mellitus and hypertension. Interventricular septal thickening and LV mass index were similar in all 3 groups. Results suggest that LV wall stiffness is greater in the diabetic heart than in the hypertensive heart, and the examination of LV diastolic dysfunction using the Valsalva maneuver is useful in evaluating the myocardial stiffness in diabetes mellitus.
    View full abstract
    Download PDF (372K)
  • Efficacy of Low-dose Gliclazide in Patients with Type 2 Diabetes Previously Treated with Rapid-acting Insulinotropic Agent or Sulfonylurea other than Gliclazide
    Masashi Shimoda, Naomasa Hayakawa, Fuminori Tatsumi, Kazuhito Tawaramo ...
    2008 Volume 51 Issue 3 Pages 221-225
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.221
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Type 2 diabetic patients previously treated with rapid-acting insulinotropic agent (glinide) or a sulfonylurea other than gliclazide, were treated with low-dose gliclazide (less than 40 mg, daily dose) for 12 months to counter poor glycemic control or hypoglycemic events, and efficacy was evaluated. Subjects were 13 randomly selected patients previously treated with glinide (glinide group) and 14 treated with sulfonylurea (SU group). The glinide group's average age was 65.6 years, BMI 24.3 kg/m2, and diabetes duration 11.0 years at baseline. The SU group's average age was 67.1 years, BMI 23.4 kg/m2, and diabetes duratiun 18.1 years at baseline. HbA1c in the glinide group decreased significantly from 8.5±0.5% at baseline to 7.0±0.4% at 12 months end points (p<0.005 vs baseline). HbA1c in the SU group decreased from 7.6±0.5% to 7.1±0.4% (p=0.141 vs baseline), and a significant weight reduction was observed (p<0.05). No episode of hypoglycemia was reported during observation in either group. Results suggest that low-dose gliclazide is useful in treating type 2 diabetes.
    View full abstract
    Download PDF (320K)
  • Improvement in Glycemic Control with Insulin Lispro Mixture-50 Three Times a Day
    Kohei Ogawa, Masaya Akao, Manabu Shimizu, Yoshinari Hayashi, Naotuka O ...
    2008 Volume 51 Issue 3 Pages 227-232
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.227
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Insulin Lispro Mixture-50 contains 50% insulin lispro, a rapid-acting insulin analog, and 50% insulin lispro protamine suspension, an intermediate-acting component.
    To evaluate the effects of Insulin Lispro Mixture-50 three times a day, type 2 diabetic patients already treated with insulin and inadequately controlled (n=28) were assigned to switch from insulin to 3 months of treatment with Insulin Lispro Mixture-50 three times a day. As the endpoint, HbA1c decreased significantly from 8.01% to 7.49% overall. Compared to groups categorized with insulin used before switching, HbA1c improved significantly in the group switching from premixed human insulin twice a day and the group getting Insulin Aspart Mixture-30 three times a day.
    Results of a questionnaire on the change of the injector and insulin indicated that it was a good answer for both.
    Insulin Lispro Mixture-50 three times a day thus appears to be useful in improving glycemic control.
    View full abstract
    Download PDF (314K)
Case Report
Report
  • Cancer Incidence in Type 2 Diabetic Outpatients
    Shizuka Kaneko, Yoshihiro Kuwabara, Yuichi Sato, Mihoko Takehiro
    2008 Volume 51 Issue 3 Pages 251-256
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.251
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The number of patients with type 2 diabetes is rapidly increasing in Japan, as is the number of patients with cancer. We studied the association between type 2 diabetes and cancer in diabetic outpatients who visit for first examinations or come for regular examination. Of 639 diabetic patients, 24 were found to have cancer. We found that 54.2% of the cancer patients were first-visit patients, i.e., 5.4% of all first-visit patients. Of revisitors, 2.8% had cancer. All cancer occurrence was higher in diabetic patients than the age-matched general Japanese population. Diabetic patients should therefore be examined carefully for both diabetes-related vasculopathy and occult cancer.
    View full abstract
    Download PDF (270K)
Co-medical
Report of the Committee
  • Report of the Japan Diabetes Society's Committee on the Diagnostic Criteria for Diabetes Mellitus and Glucose Metabolism Disorder
    —A New Category of Fasting Plasma Glucose Values:“high-normal”
    Takashi Kadowaki, Masakazu Haneda, Makoto Tominaga, Nobuhiro Yamada, Y ...
    2008 Volume 51 Issue 3 Pages 281-283
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.281
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The Japan Diabetes Society established fasting plasma glucose (FPG) values<110 mg/dl as the normal range (Diabetes Research and Clinical Practice 55: 73, 2002). Recent epidemiological data in Japan show that subjects with FPG values of 100 to 109 mg/dl, which are in the normal range, develop diabetes at a higher rate than subjects with FPG values<100 mg/dl. Moreover, 25-40% of the subjects with FPG 100 to 109 mg/dl would be diagnosed as the borderline type or diabetic type on a 75 g oral glucose tolerance test (OGTT). In order not to overlook the risk that subjects in this group will develop diabetes and at the same time not to mislabel the 60-75% of them as having the borderline type, who would be found to have the normal type on an OGTT, the committee recommends that subjects with a FPG value of 100 to 109 mg/dl be classified as “high-normal” in the normal range in the definition of glucose metabolism disorder. It is recommended that subjects with a “high-normal” FPG value undergo a 75 g OGTT for diagnosis as normal-, borderline-, or diabetic-type. Until the 75 g OGTT is performed, such subjects should be followed up as having a “high-normal” FPG value and appropriate lifestyle modifications, including improvement of obesity should be implemented according to the condition of the individual subject.
    View full abstract
    Download PDF (204K)
  • Report of Committee on Early-onset Type 2 Diabetes Mellitus
    —Preliminary Research on Actual Situation of Early-onset Type 2 Diabetes Mellitus
    Y. Iwamoto, N. Tajima, R. Nishimura, N. Yoshioka, N. Sasaki, T. Urakam ...
    2008 Volume 51 Issue 3 Pages 285-287
    Published: 2008
    Released on J-STAGE: May 20, 2009
    DOIhttps://doi.org/10.11213/tonyobyo.51.285
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    [in Japanese]
    View full abstract
    Download PDF (216K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top